Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update Tvardi Therapeutics (NASDAQ: TVRD) reported fourth-quarter and full-year 2025 results and provided a clinical update. Cash, cash equivalents and short-term investments were $30.8M as of Dec 31, 2025, with a runway expected into Q4 2026. Net loss for 2025 was $18.2M versus $29.4M in 2024.Clinical milestones: topline healthy volunteer data for next-generation STAT3 inhibitor TTI-109 expected in Q2 2026; topline Phase 1b/2 REVERT LIVER CANCER results for TTI-101 anticipated in H2 2026. REVERT IPF analysis showed a 9.4% fibrosis reduction vs 2.4% for placebo.

#TVRD Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

www.stocktitan.net/news/TVRD/tvardi-therape...

Most Searched, Tuesday January 13, 2026 – Crystal Equity Research

Most searched small-cap stocks, Tue Jan 13th - #IBRX #TE #DNN #RR #AHMA #RZLV #CLSK #HIVE #PLUG #EVTV #TVRD #TRX #TLRY #KSS #KRP #HYMC #FTFT #FOLGF #AXTI #AEVA - More: crystalequityresearch.com/most-searche... - #smallcap

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update Tvardi Therapeutics (NASDAQ: TVRD) reported third quarter 2025 results and a business update highlighting clinical and cash milestones. The company expects topline Phase 2 TTI-101 HCC data in H1 2026 and healthy volunteer results for next-generation TTI-109 in H1 2026 after its IND went into effect. In October, Tvardi reported that the Phase 2 REVERT IPF trial did not meet its goals and is conducting additional analyses. Financially, Q3 R&D was $3.6M versus $4.8M year-ago, G&A rose to $2.3M from $0.9M, net loss was $5.5M, and cash plus short-term investments were $36.5M, with a runway into Q4 2026.

#TVRD Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

www.stocktitan.net/news/TVRD/tvardi-therape...

Trade Alerts, Tuesday October 14, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Tue Oct 14th - #SBFM #PMEC #NVA #GWAV #EDBL #DRDB #WKEY #ULBI #TVRD #SBLX #REKR #QRHC #MNTS #GURE #CASS #ALM #MCRP #TTI #CCRD #AKA - More: crystalequityresearch.com/trade-alerts... - #smallcap

Trade Alerts, Monday October 13, 2025 – Crystal Equity Research

Small-cap stocks with strong volume declines, Mon Oct 13th - #VCIG #TBH #NVX #ELAB #TVRD #PDEX #BYND #ASST #ENFY - More: crystalequityresearch.com/trade-alerts... - #smallcap

PRISM MarketView M☀️rning M☀️vers:
Top Gainers
#PMAX up + 117%
#QNRX up +151%
#GWM up +141%
#ELBM up +65%
Top Decliners
#TVRD down -87.7%
#BYND down -54.9%

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today provided an update on preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The REVERT IPF Phase 2 clinical...

#TVRD Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/TVRD/tvardi-therape...

Tvardi Posts Q2 Net Income Turnaround | The Motley Fool

#TVRD #097dd293-abf4-4e3b-86a6-6f1312670867 #data-news

Origin | Interest | Match

Tvardi's Phase 2 IPF Drug Shows Promise as Q2 Earnings Beat Expectations with $4.2M Profit Biotech firm posts $4.2M Q2 profit with $41M cash runway into Q4 2026. Key Phase 2 IPF trial fully enrolled, targeting Q4 readout for STAT3 inhibitor TTI-101. Get insights.

#TVRD Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

www.stocktitan.net/news/TVRD/tvardi-therape...

Breakthrough IPF Treatment Reaches Major Milestone: Phase 2 Trial of First-in-Class STAT3 Inhibitor Completes Enrollment Novel STAT3 inhibitor TTI-101 advances in treating idiopathic pulmonary fibrosis. Unique dual mechanism shows promise in reversing lung damage. Get trial insights.

#TVRD Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

www.stocktitan.net/news/TVRD/tvardi-therape...

Tvardi's $52M Cash Injection Powers Multiple Phase 2 Trials After Cara Therapeutics Merger Success Fresh $52M funding extends operations through 2026. Key Phase 2 readouts ahead for STAT3 inhibitor in IPF and liver cancer. See pipeline milestones.

#TVRD Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

www.stocktitan.net/news/TVRD/tvardi-therape...

Breakthrough STAT3 Inhibitor Targets Untreated 60% of IPF Disease Markers, Outperforms Current Therapies Novel STAT3 inhibitor TTI-101 demonstrates superior fibrosis suppression in IPF treatment study. Addresses previously untreated disease markers. See breakthrough data.

#TVRD Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

www.stocktitan.net/news/TVRD/tvardi-therape...